Mechanism of action

MabThera effectively eradicates CD20+ cells in lymphoma patients by several distinct mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and apoptosis¹.

References

Olszewski AJ, Grossbard ML. Empowering Sci STKE 2004; 2004: pe30.

Your feedback is valuable to MabThera

Sorry - your browser does not support the IFRAME tag.

Prognostic factors

Prognostic factors provide a method of assessing the likely course of a disease and help drive treatment decisions.

Learn more

Brief prescribing information

Download the Brief Prescribing Information for MabThera.

Now for download

MabThera product characteristics

Find out more about the characteristics of MabThera and how it is used in the treatment of non-Hodgkin's lymphoma.